Synonyms: LY-3473329 | LY3473329
Compound class:
Synthetic organic
Comment: Muvalaplin (LY3473329) is an orally bioavailable small molecule that disrupts the binding of apolipoprotein(a) to apolipoprotein B100, thus blocking the formation of lipoprotein(a) [1]. It was designed to treat atherosclerotic disease. Muvalaplin does not bind to plasminogen.
|
|
No information available. |
Summary of Clinical Use ![]() |
Muvalaplin has advanced to clinical evaluation as a treatment for atherosclerotic cardiovascular disease (ASCVD). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04472676 | A Study of LY3473329 in Healthy Participants | Phase 1 Interventional | Eli Lilly and Company | 1 | |
NCT05563246 | A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events | Phase 2 Interventional | Eli Lilly and Company |